Department of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.
Histol Histopathol. 2010 Jun;25(6):733-9. doi: 10.14670/HH-25.733.
T-cell receptor gamma chain alternative reading frame protein (TARP) has recently been proposed as being up-regulated in prostate cancer (PCA). Additionally, TARP has been proposed as a potential therapeutic target for cancer therapy. We analysed the protein expression of TARP in a large well characterised prostate cancer cohort to assess its diagnostic and prognostic value. Methodologically, we constructed a tissue microarray comprising more than 600 PCA cases including matching benign prostate tissue. TARP protein expression was carefully analysed and associated with clinico-pathological parameters, PSA-relapse free survival and expression data of established and proposed diagnostic markers (AMACR, p63, GOLPH2). Our results show that TARP is significantly over-expressed in the vast majority (approximately 85%) of PCA in comparison to non neoplastic prostate tissue. Its expression was associated with conventional markers of unfavourable and more aggressive tumour behaviour. However, a prognostic value of TARP could not be found. The diagnostic value of TARP is limited in comparison to AMACR, p63 or GOLPH2. Since TARP specific immunologic therapy regimen are currently being tested, the high frequency of TARP over-expression in PCA conveys a high potential for a predictive and potentially therapeutic use of this biomarker.
T 细胞受体 γ 链可变读码框蛋白（TARP）最近被提出在前列腺癌（PCA）中上调。此外，TARP 被提议作为癌症治疗的潜在治疗靶点。我们分析了大量经过良好特征描述的前列腺癌队列中的 TARP 蛋白表达，以评估其诊断和预后价值。在方法学上，我们构建了一个组织微阵列，其中包含超过 600 例 PCA 病例，包括匹配的良性前列腺组织。仔细分析了 TARP 蛋白的表达，并将其与临床病理参数、PSA 无复发生存率以及既定和提议的诊断标志物（AMACR、p63、GOLPH2）的表达数据相关联。我们的结果表明，与非肿瘤性前列腺组织相比，TARP 在绝大多数（约 85%）PCA 中明显过表达。它的表达与不利和侵袭性更强的肿瘤行为的常规标志物相关。然而，未能发现 TARP 的预后价值。与 AMACR、p63 或 GOLPH2 相比，TARP 的诊断价值有限。由于目前正在测试 TARP 特异性免疫治疗方案，因此 TARP 在 PCA 中的高频率过表达为该生物标志物的预测和潜在治疗用途提供了很高的潜力。
